Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations

Multifunctional Lipid-Based Nanoparticles for Codelivery of Anticancer Drugs and siRNA for Treatment of Non-Small Cell Lung Cancer with Different Level of Resistance and EGFR Mutations

Resistance to chemotherapy, enhanced proliferation, invasion, angiogenesis, and metastasis (RPIAM) represent major obstacles that limit the efficacy of cancer treatment especially in advanced stages of cancer. Overcoming or suppressing RPIAM can dramatically improve the treatment outcome. Non-small...

Full description

Bibliographic Details
Main Authors:	Joydeb Majumder, Tamara Minko
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Series:	Pharmaceutics
Subjects:	EGFR mutated and gefitinib-resistant NSCLC lipid nanoparticles siRNA LHRH paclitaxel
Online Access:	https://www.mdpi.com/1999-4923/13/7/1063

Similar Items

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
by: Kim JS, et al.
Published: (2018-08-01)

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation
by: Tingting Liao, et al.
Published: (2022-09-01)

Cabazitaxel-loaded human serum albumin nanoparticles combined with TGFβ-1 siRNA lipid nanoparticles for the treatment of paclitaxel-resistant non-small cell lung cancer
by: Tiantian Tan, et al.
Published: (2023-07-01)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
by: Zhonghan Zhang, et al.
Published: (2020-06-01)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
by: Shu Y, et al.
Published: (2021-11-01)

The codelivery of siRNA and QDs by pH-responsive micelle for hepatoma cancer cells
by: Cao, Zhonglin, et al.
Published: (2020)

Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy
by: Bi Y, et al.
Published: (2018-10-01)

Trimethyl-Chitosan Coated Gold Nanoparticles Enhance Delivery, Cellular Uptake and Gene Silencing Effect of EGFR-siRNA in Breast Cancer Cells
by: Leila Baghani, et al.
Published: (2022-04-01)

Brain-targeted polymersome codelivery of siRNA and temozolomide for effective glioblastoma chemo-RNAi synergistic therapy
by: Meng Zheng, et al.
Published: (2022-07-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)

FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
by: Yi Xiao, et al.
Published: (2018-06-01)

Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery
by: Wanyi Tai
Published: (2019-06-01)

The Codelivery of siRNA and QDs by pH-Responsive Micelle for Hepatoma Cancer Cells
by: Zhonglin Cao, et al.
Published: (2019-10-01)

Polyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA
by: Elzeny H, et al.
Published: (2017-02-01)

Inhibition of EGFR Signaling Protects from Mucormycosis
by: Tonya N. Watkins, et al.
Published: (2018-09-01)

Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy
by: Chung-Yu Huang, et al.
Published: (2020-01-01)

Near Total Regression of Diffuse Brain Metastases in Adenocarcinoma of the Lung with an EGFR Exon 19 Mutation: A Case Report and Review of the Literature
by: Wen-Hao Tang, et al.
Published: (2011-09-01)

Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations
by: Naoto Aiko, et al.
Published: (2018-10-01)

Engineering siRNA therapeutics: challenges and strategies
by: Syed Saqib Ali Zaidi, et al.
Published: (2023-10-01)

Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
by: Alexey Berezhnoy, et al.
Published: (2012-01-01)

A Multifunctional Hybrid Nanocarrier for Non-Invasive siRNA Delivery to the Retina
by: Shogo Nishida, et al.
Published: (2023-02-01)

AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways
by: Yi-Hua Lai, et al.
Published: (2017-11-01)

Multifunctional polymeric micelles for delivery of drugs and siRNA
by: Aditi M. Jhaveri, et al.
Published: (2014-04-01)

Construction of PEI‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer
by: Guixue Yang, et al.
Published: (2022-11-01)

Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer
by: Zhang X, et al.
Published: (2019-04-01)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
by: Shigetoshi Nishihara, et al.
Published: (2022-11-01)

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
by: Stephen V. Liu, et al.
Published: (2023-09-01)

Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know
by: Alexander Meisel
Published: (2020-03-01)

Dual Targeted Nanoparticles for the Codelivery of Doxorubicin and siRNA Cocktails to Overcome Ovarian Cancer Stem Cells
by: Li Chen, et al.
Published: (2023-07-01)

Nanoparticles and siRNA: A new era in therapeutics?
by: María Dolores Pérez-Carrión, et al.
Published: (2024-03-01)

Celastrol Induces Apoptosis in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells via Caspases-Dependent Pathways and Hsp90 Client Protein Degradation
by: Xing-Xing Fan, et al.
Published: (2014-03-01)

Dendrimers for siRNA Delivery
by: Swati Biswas, et al.
Published: (2013-02-01)

Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation
by: Weiran Cao, et al.
Published: (2022-09-01)

Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment
by: Jiatao Liao, et al.
Published: (2021-06-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

Implications of siRNA Therapy in Bone Health: Silencing Communicates
by: Puneetpal Singh, et al.
Published: (2024-01-01)

Structural Modifications of siRNA Improve Its Performance In Vivo
by: Ivan V. Chernikov, et al.
Published: (2023-01-01)

Effect of the amount of cationic lipid used to complex siRNA on the cytotoxicity and proinflammatory activity of siRNA-solid lipid nanoparticles
by: Mahmoud S. Hanafy, et al.
Published: (2023-12-01)

Codelivery of HBx-siRNA and Plasmid Encoding IL-12 for Inhibition of Hepatitis B Virus and Reactivation of Antiviral Immunity
by: Yan Mu, et al.
Published: (2022-07-01)